U.S. Other Utilities Stock News

Annexon (ANNX) is in focus after reporting positive Phase 3 data for tanruprubart in Guillain-Barré syndrome, filing in Europe, planning a US FDA submission, and sharing progress on vonaprument in geographic atrophy. See our latest analysis for Annexon. Annexon’s recent clinical and regulatory updates arrive after a mixed price pattern, with the stock up 17.41% on a 1 month share price return and 23.67% year to date, but down 11.31% over 3 months. The 1 year total shareholder return of 150%...

Packaging Corporation of America stock has more than doubled over the past five years, yet the valuation signals are split, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a large discount while market multiples paint a richer picture. Shareholders have seen a 102.1% return over 5 years, which puts the recent share price in focus for anyone thinking about what is already priced in. On the positive side, steady cash generation from packaging demand can support the DCF...

Insmed reported positive 12 month open label extension data for TPIP in pulmonary arterial hypertension. The study showed sustained improvements in six minute walk distance and NT proBNP, with no new safety signals reported. These results support Insmed’s plan to advance TPIP into a Phase 3 randomized, controlled trial. For investors tracking Insmed, ticker NasdaqGS:INSM, the TPIP update adds a fresh data point to a stock that has moved sharply over multi year periods, with a very large 3...

With SpaceX stock under pressure, higher short interest and bond market stress are pushing some investors to reassess where they want to take risk in the space and aerospace theme. That is where a value-focused screener can help. By filtering for companies with market caps above $300 million, lower price multiples, moderate balance sheet risk and dividend potential, it aims to surface stocks that may be better aligned with a more cautious mood. This article walks through 3 stocks exposed to...

Flex stock has delivered a very large 5 year gain, yet the current valuation checks suggest the shares still trade at a discount, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to undervaluation despite the recent pullback. Over the last 5 years, Flex has returned about 8.9x, which means recent weakness sits on top of a very strong long term share price performance. The expanded manufacturing partnership with Cerebras for AI accelerator...

City Holding stock is coming off a strong five year run, yet the valuation signals are split, with an intrinsic value estimate from the Excess Returns model pointing to upside while the market multiple view looks less forgiving. City Holding has returned 112.6% over the past 5 years, which puts more pressure on today’s valuation to be supported by future fundamentals. For a regional bank, the key support for the share price can come from consistent profitability and a resilient balance...

AvalonBay Communities recently reported that its second-quarter 2026 results followed a period of strong U.S. apartment demand, with same-store residential occupancy holding above 96%, even as elevated borrowing costs and interest expenses remained a drag. This combination of firm occupancy going into the peak leasing season and ongoing financing headwinds highlights the tension between operational strength and capital market pressures for the REIT. We’ll now examine how resilient occupancy...

Vericel stock has delivered a 32.0% return over the past year, yet its current valuation checks lean expensive, raising the question of how much of the story is already reflected in the share price. Over the last 1 year, Vericel has returned 32.0%. This puts recent shareholder gains front and center in any discussion of what the stock is worth today. For a company like Vericel, expectations around sustaining growth in its therapies can support the current pricing. However, any setback in...

Albertsons Companies stock has slipped over the past three years, even as some valuation checks now suggest the shares may be pricing in more caution than the current fundamentals alone would imply. Over the past three years, Albertsons Companies has delivered a total return that is down 25.4%. This puts recent price moves in the context of a longer period of weak shareholder outcomes. The push into AI-driven retail media through the Criteo integration can support margin and cash flow...

Molina Healthcare's stock has rallied strongly in the short term, yet the longer three year return is still deeply negative and the broader valuation checks lean expensive. This raises the question of how much of the Illinois Medicaid contract win is already reflected in the current price. Over the past three years, Molina Healthcare shares have declined 29.2%, which suggests that the recent strength is working off a weak longer term base rather than building on steady gains. The newly...

Watsco stock sits in an awkward spot on valuation today, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to almost 30% upside while traditional market multiples paint it as expensive and the broader checks give it a low value score. Watsco has returned 45.3% over the past 5 years, which is a solid outcome that makes the current price level important to scrutinize. Expectations for steady cash generation can support the DCF view of upside. However, any pressure on...

Regulatory shock puts Edwards Lifesciences stock under a sharper lens The Federal Trade Commission’s record $12 million penalty tied to Edwards Lifesciences (EW) acquisition of JC Medical, along with new restrictions on future TAVR AR deals, has pushed the stock’s regulatory risk profile into sharper focus. See our latest analysis for Edwards Lifesciences. Since the FTC action, Edwards Lifesciences’ recent 1 day share price return of 2.4% and 7 day return of 7.03% show selling pressure...

Recently, AXIS Capital Holdings’ strong track record of positive earnings surprises and a positive Zacks Earnings ESP of 3.82% highlighted rising analyst optimism ahead of its latest quarterly report. This pattern of earnings outperformance and upward estimate revisions has drawn attention to how consistently improving expectations can influence sentiment around the insurer’s near‑term performance. Next, we’ll examine how this positive earnings surprise momentum and analyst estimate...

We wouldn't blame Braze, Inc. ( NASDAQ:BRZE ) shareholders if they were a little worried about the fact that Astha...

Centrus Energy stock has delivered a very large 5 year gain, yet the current valuation checks lean expensive, with the broader model assigning it a low overall value score. Over the past 5 years, Centrus Energy has returned about 5.5x, which sets a high bar for any further upside to be justified by fundamentals. Future cash generation from its enrichment and fuel-related activities can support the current share price, but any setback to margins or project timing may quickly pressure what...

Softer than expected inflation data prompted investors to reassess interest rate expectations, and United Bankshares (UBSI) moved higher alongside regional peers as markets evaluated the potential for relief on funding costs and loan demand. See our latest analysis for United Bankshares. At a share price of $47.58, United Bankshares has a 1 month share price return of 7.67% and a year to date share price return of 23.94%. The 1 year total shareholder return of 32.45% and 5 year total...

Celcuity stock has delivered a very large 3 year return, yet its recent pullback and a mixed set of valuation checks raise questions about how much of the good news around its newly approved breast cancer therapy is already reflected in the price. Over the last 3 years Celcuity has returned roughly 7x, which sets a high bar for further gains given how much value has already been created for existing shareholders. The full FDA approval of REVTORPYK for advanced HR positive, HER2 negative...

We wouldn't blame Arista Networks, Inc. ( NYSE:ANET ) shareholders if they were a little worried about the fact that...

With tech stocks under pressure and expectations running high this earnings season, some investors are looking more closely at areas of the market that can sometimes feel steadier when sentiment turns cautious. This defensive sectors screener focuses on consumer staples, health care, and real estate companies that meet certain size and quality criteria, and are directly exposed to the latest news around earnings surprises, guidance resets, and interest rate expectations. In this article, you...

After roughly doubling over the past five years, ePlus stock now sits at a level where the Discounted Cash Flow (DCF) intrinsic value estimate suggests the shares trade at a premium. Broader valuation checks point to a more mixed picture rather than a clear warning sign. ePlus has returned about 102% over the past five years, so the stock is no longer an obvious bargain based purely on its recent track record. Strong recent momentum in the IT distribution and solutions business can support...

Anyone interested in FB Financial Corporation ( NYSE:FBK ) should probably be aware that the Chief Accounting Officer...

We can readily understand why investors are attracted to unprofitable companies. By way of example, Camp4 Therapeutics...

RenaissanceRe Holdings stock has delivered a 124.7% return over the past 5 years, and the current valuation checks indicate that the shares may still be inexpensive relative to the company’s fundamentals. RenaissanceRe Holdings' 124.7% 5-year return indicates that long-term holders have already seen solid gains, so any further upside may depend on whether current expectations for the business remain intact. For a reinsurer like RenaissanceRe Holdings, the outlook for underwriting...

We wouldn't blame Incyte Corporation ( NASDAQ:INCY ) shareholders if they were a little worried about the fact that...